from top gun, to litte pistol, 7c wow !!, page-22

Neo, check your research.

They have $63 million available to them (as at 31 March), including the $20m through Novaquest.

The $6m per quarter reflected higher spend on the discovery assets they want to sell off in the near term- it will not be ongoing.

Also patients on Kalydeco still need a nebulizer or other assistance (such as Bronchitol) to clear their lungs. Bronchitol is complementary to Kalydeco and trials are showing the both together deliver great outcomes for patients.

The CF303 trial is a tie breaker trial and will be in an adult population where significance in the primary endpoint was achieved...twice.